Study Subject Enrollment Sample Clauses

Study Subject Enrollment. Institution 2.
Sample 1
AutoNDA by SimpleDocs
Study Subject Enrollment. Institution and/or Investigator shall use its reasonable good 2. Zařazování subjektů do studie. Zdravotnické zařízení a/nebo zkoušející vyvinou faith efforts to enroll Study Subjects who meet the requirements of the Protocol or as otherwise set forth in the written instructions provided by the Sponsor. After the fourth th) Study Subject is randomized to the Study at the Institution, Institution or Investigator must seek Sponsor approval prior to initiating additional screening activities to enroll more Study Subjects after the th Study Subject. Sponsor approval must be documented in writing via email or other written approval. Payments for all Subjects enrolled by Institution with Sponsor written approval, are subject to the terms of this Agreement, payment terms and the Study Budget. v dobré víře přiměřené úsilí a zařadí do studie subjekty, které splňují požadavky protokolu nebo jiné požadavky uvedené v písemných pokynech zadavatele. Poté, co dojde k randomizaci čtvrtého subjektu studie ve zdravotnickém zařízení, musí zdravotnické zařízení nebo zkoušející získat souhlas zadavatele xxxxxxx, xxx xxxxxx xxxxxxxxx screening pro zařazení dalších subjektů studie po subjektu studie. Souhlas zadavatele musí být doložen písemně ve formě e-mailu nebo jiného písemného souhlasu. Platby pro všechny subjekty studie zařazené zdravotnickým zařízením s písemným souhlasem zadavatele podléhají podmínkám této smlouvy, platebním podmínkám a rozpočtu studie.
Sample 1
Study Subject Enrollment. Institution has agreed that Principal Investigator will enroll Study Subjects in the Study in accordance with the Protocol and in accordance with IEC and/or RA approval. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved, if applicable. 7.
Sample 1
Study Subject Enrollment. Upon receipt of any notice of termination or suspension, University and Principal Investigator agree that no additional Study subjects will be enrolled in the Study. Any Study subjects already enrolled in the Study will be phased-out as deemed appropriate by Company and Principal Investigator. Company shall give University a minimum of fourteen (14) days notice before closing enrollment so University does not incur unnecessary costs or disappoint potential Subjects that are in the recruiting process.
Sample 1
Study Subject Enrollment hodnocení dodají Instituci dostatečná množství Hodnoceného přípravku k provádění Klinického hodnocení dle podmínek v Protokolu.
Sample 1
Study Subject Enrollment. Institution agrees to enroll qualified Study Subjects in the Study, in accordance with the Protocol and in accordance with IEC and/or RA approval. A qualified Study Subject is one whom meets all the Protocol criteria for participation in the Study. Principal Investigator announces the inclusion of the Study Subject to the Study specifying the decision number of the Study and the date of inclusion of the Study Subject in the Study to the health insurance company conducting the Public Health Insurance of Study Subject immediately after inclusion of the Study Subject to the Study in accordance with the provisions of Section 26 of No. 576/2004 Coll.. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved or before Institution has enrolled the minimum number of Study Subjects. Protocol does not require hospitalization during the course of the Study. 6.
Sample 1
Study Subject Enrollment. Institution has agreed to enroll Study Subjects in the Study in accordance with the Protocol and in accordance with IEC and Competent Authority approvals. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved, if applicable. Protocol does not require hospitalization during the course of the Study. Informed Consent. Institution shall ensure that the Informed Consent Form (“ICF”), which must comply with Applicable Law, as approved by Sponsor, Sponsor’s Designee (Syneos Health), the IEC and, if required, the Competent Authority, is properly executed by each Study Subject before (i) such Study Subject is enrolled in the Study; and (ii) any personal data of such Study Subject is processed. 7.
Sample 1
AutoNDA by SimpleDocs
Study Subject Enrollment. Institution and/or Investigator shall use its reasonable good faith efforts to enroll Study Subjects who meet the requirements of the Protocol or as otherwise set forth in the written instructions provided by the Sponsor. After the fourth (4th) Study Subject is randomized to the Study at the Institution, Institution or Investigator must seek Sponsor approval prior to initiating additional screening activities to enroll more Study Subjects after the 4th Study Subject. Sponsor approval must be documented in writing via email or other written approval. Payments for all Subjects enrolled by Institution with sponsor written approval are subject to the terms of this Agreement, payment terms and the Study Budget. 2.
Sample 1
Study Subject Enrollment. Institution and/or Investigator shall use its reasonable good faith efforts to enroll Study Subjects who meet 2. Zařazování subjektů do studie. Zdravotnické zařízení a/nebo zkoušející vyvinou v dobré víře přiměřené úsilí a zařadí do studie
Sample 1

Related to Study Subject Enrollment

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Tests 7.7.1 If the Contract Documents, laws, ordinances, rules, regulations or orders of any public authority having jurisdiction require any portion of the Work to be inspected, tested or approved, the Contractor shall give the Architect timely notice of its readiness so the Architect may observe such inspection, testing or approval. The Contractor shall bear all costs of such inspections, tests or approvals conducted by public authorities.

Time is Money Join Law Insider Premium to draft better contracts faster.